- Home
- IPHA vs PRE Comparison
IPHA vs PRE Comparison
Compare IPHA & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | PRE |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | France | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.2M | 131.3M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | IPHA | PRE |
|---|---|---|
| Price | $1.96 | $14.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 565.0K | 136.0K |
| Earning Date | 09-17-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,839,695.00 | ★ $77,079,000.00 |
| Revenue This Year | $22.29 | $202.46 |
| Revenue Next Year | $43.90 | $103.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 201.54 |
| 52 Week Low | $1.43 | $3.10 |
| 52 Week High | $3.51 | $17.99 |
Technical Indicators
Market Signals| Indicator | IPHA | PRE |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 51.71 |
| Support Level | $1.85 | $12.93 |
| Resistance Level | $2.01 | $14.97 |
| Average True Range (ATR) | 0.08 | 1.18 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 69.64 | 65.61 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About PRE Prenetics Global Limited
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.